off-label use of glp-1 agonists for obesity in 2016 Revolutionizing treatment: The emerging role receptor and next-generation pharmacotherapies Managing Side Effects and Dosing

Furthermore, most available studies are of short duration and lack long-term follow-up to assess whether repeated or chronic IF leads to sustained alterations in thyroid function or clinically meaningful hypothyroidism [60] (Table 2)

Glucagon-like peptide-1 receptor agonists (GLP-1-RA) have been proposed as a potential adjunctive treatment for patients with SO, who achieve suboptimal outcomes after BS

doi: 10.3233/JAD-141332 181

Solid lines are irrelevant dsRNA treatments and dashed lines are dsTGR treatments

GCN2iB increases left ventricular ejection fraction, while reducing fasting blood glucose and myocardial fibrosis

You might say they are actually one size fits no one requiring multiple adjustments to achieve the desired outcome